Hepatobiliary manifestations of ulcerative colitis: An example of gut-liver crosstalk

Gastroenterology Report

Volumn 2, Issue 3, 2014, Pages 193-200

  Navaneethan, Udayakumar ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Liver transplantation; Primary sclerosing cholangitis; Restorative proctocolectomy; Ulcerative colitis

Indexed keywords

EID: 84948976345     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou036     Document Type: Review

References (106)

1. Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extra-intestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22.
2. Trikudanathan G, Venkatesh PG and Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 2012;72:2333-49.
3. Bernstein CN, Wajda A and Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36.
4. Mendoza JL, Lana R, Taxonera C et al. Extra-intestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005;125:297-300.
5. Venkatesh PG, Navaneethan U and Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis 2011; 12:245-56.
6. Navaneethan U and Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1598-619.
7. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23.
8. Smith M and Loe S. Sclerosing cholangitis: review of recent case reports and associated diseases and four new cases. Am J Surg 1965;110:239-46.
9. Farrant JM, Doherty DG, Donaldson PT et al. Amino acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992;16:390-5.
10. Olerup O, Olsson R, Hultcrantz R et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-8.
11. Cortes A and Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011;13:101.
12. Mitro N, Godio C, De Fabiani E et al. Insights in the regulation of cholesterol 7 alpha-hydroxylase gene reveal a target for modulating bile acid synthesis. Hepatology 2007;46:885-97.
13. Halilbasic E, Claudel T and Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013;58:155-68.
14. Trauner M and Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011;140: 1120-5, e1-12.
15. Modica S, Petruzzelli M, Bellafante E et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012;142:355-65, e1-4.
16. Schaap FG, van der Gaag NA, Gouma DJ et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228-35.
17. Triantis V, Saeland E, Bijl N et al. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology 2010;52:656-66.
18. Zweers SJ, Booij KA, Komuta M et al. The human gall bladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012;55:575-83.
19. Saarinen S, Olerup O and Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000;95:3195-9.
20. Mulder AH, Horst G, Haagsma EB et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411-7.
21. Bansi DS, Fleming KA and Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996; 38:384-9.
22. Terjung B and Spengler U. Role of autoantibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 2005; 28:115-33.
23. Terjung B, Spengler U, Sauerbruch T et al. 'Atypical p-ANCA' in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000;119:310-22.
24. Mandal A, Dasgupta A, Jeffers L et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 1994;106:185-92.
25. O'Mahony CA and Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21.
26. Worthington J, Cullen S and Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28: 93-103.
27. McGovern DP, Jones MR, Taylor KD et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet 2010;19:3468-76.
28. Rausch P, Rehman A, Kunzel S et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (secretor) genotype. Proc Natl Acad Sci USA 2011;108: 19030-5.
29. Devkota S, Wang Y, Musch MW et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL 10-/-mice. Nature 2012;487:104-8.
30. Fausa O, Schrumpf E and Elgio K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31-9.
31. Aoki CA, Bowlus CL and Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005;4:137-43.
32. Kono K, Ohnishi K, Omata K et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988;94:787-96.
33. Terjung B and Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a 'leaky gut'? Clin Rev Allergy Immunol 2009;36:40-51.
34. Adams DH and Eksteen B. Aberrant homing of mucosal T-cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6:244-51.
35. Liaskou E, Karikoski M, Reynolds GM et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011;53:661-72.
36. Lalor PF, Tuncer C, Weston C et al. Vascular adhesion protein-1 as a potential therapeutic target in liver disease. Ann N Y Acad Sci 2007;1110:485-96.
37. Loftus EV, Sandborn WJ, Lindor KD et al. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997;3:288-302.
38. Faubion WA, Loftus EV, Sandborn WJ et al. Pediatric 'PSC-IBD': a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001;33: 296-300.
39. Loftus EV, Harewood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6.
40. Heuschen U, Hinz U, Allemeyer E et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120:841-7.
41. Joo M, Abreu-e-Lima P, Farraye F et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009;33:854-62.
42. Lundqvist K and Broome? U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997;40:451-6.
43. Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-9.
44. Broome U, Lofberg R, Lundqvist K et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 1995;38:1301-5.
45. Shen B, Bennett AE, Navaneethan U et al. Primary sclerosing cholangitis is associated with endoscopic and histological inflammation of the distal afferent limb in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis 2011;17:1890-900.
46. Navaneethan U, Venkatesh PG, Mukewar S et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:540-6.
47. Rust C and Brand S. PSC: Protect and serve with colitis: does it help the liver to have severe ulcerative colitis? Gut 2011;60:1165-6.
48. Marelli L, Xirouchakis E, Kalambokis G et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011;60:1224-8.
49. Soetikno R, Lin O and Heidenreich P. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56: 48-54.
50. Navaneethan U, Kochhar G, Venkatesh PG et al. Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc 2012;75:1045-105e1.
51. Navaneethan U, Kochhar G, Venkatesh PG et al. Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2013;7:974-81.
52. Navaneethan U, Venkatesh PG, Lashner BA et al. Temporal trends in colon neoplasms in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2012;6:845-51.
53. Navaneethan U, Venkatesh PG, Choudhary M et al. Elevated immunoglobulin G4 level is associated with reduced colectomy-free survival in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2013;7(2), e35-41.
54. Navaneethan U and Lashner BA. Effects of immunosuppression and liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:524-5.
55. Befeler AS, Lissoos TW, Schiano TD et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998;65:393-6.
56. Navaneethan U, Choudhary M, Venkatesh PG et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012 Mar 19. [Epub ahead of print]
57. Saldeen K, Friman S, Olausson M et al. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999;34:535-40.
58. Papatheodoridis GV, Hamilton M, Mistry PK et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998;43:639-44.
59. Jorgensen KK, Lindström L, Cvancarova M et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:517-23.
60. Wu XR, Mukewar S, Kiran RP et al. The presence of primary sclerosing cholangitis is protective for ileal pouch from Crohn's disease. Inflamm Bowel Dis 2013;19:1483-9.
61. Ludwig J, Barham SS, La Russo NF et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1:632-40.
62. MacCarty RL, La Russo NF, May GR et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology 1985;156:43-46.
63. Broome U, Olsson R, Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
64. Rabinovitz M, Gavaler JS, Schade RR et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990;11:7-11.
65. Navaneethan U, Venkatesh PG, Lashner BA et al. The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther2012, Mar 19. [Epub ahead of print].
66. Ngu JH, Gearry RB, Wright AJ et al. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9:1092-7.
67. Poritz LS and Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis Colon Rectum 2003;46:173-8.
68. Cangemi JR, Wiesner RH, Beaver SJ et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989;96:790-4.
69. Mikkola K, Kiviluoto T, Riihelä M et al. Liver involvement and its course in patients operated on for ulcerative colitis. Hepatogastroenterology 1995;42:68-72.
70. Lepistö A, Kivistö S, Kivisaari L et al. Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolectomy for ulcerative colitis. Int J Colorectal Dis 2009;24:1169-74.
71. Freeman K, Shao Z, Remzi FH et al. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol 2008;6:62-8.
72. Obusez EC, Lian L, Shao Z et al. Impact of ileal pouch-anal anastomosis on the surgical outcome of orthotopic liver transplantation for primary sclerosing cholangitis. J Crohns Colitis 2013;7:230-8.
73. Cholongitas E, Shusang V, Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-43.
74. Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis obviates the need for liver histology. Mayo Clinic Proc 2000;75:688-94.
75. Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36: 321-7.
76. Fevery J, Verslype C, Lai G et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007;52:3123-35.
77. Boberg KM, Jebsen P, Clausen OP et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-74.
78. Rudolph G, Gotthardt D, Kloeters-Plachky P et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010;53:313-7.
79. Trikudanathan G, Navaneethan U, Njei B et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:783-9.
80. Navaneethan U, Njei B, Venkatesh PG et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:943-50e3.
81. Boberg KM, Jebsen P, Clausen OP et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-74.
82. Karlsen TH and Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013;59:571-82.
83. Navaneethan U, Gutierrez NG, Venkatesh PG et al. Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study. Am J Gastroenterol2014, Apr 8. [Epub ahead of print].
84. Mir-Madjlessi SH, Farmer RG and Sivak MV Jr. Bile duct carcinoma in patients with ulcerative colitis relationship to sclerosing cholangitis: report of six cases and review of the literature. Dig Dis Sci 1987;32:145-54.
85. Erichsen R, Jepsen P, Vilstrup H et al. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009;24:513-20.
86. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62.
87. Bergquist A, Glaumann H, Persson B et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998;27: 311-6.
88. Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000;31:7-11.
89. Claessen MM, Vleggaar FP, Tytgat KM et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50:158-64.
90. Lewis JT, Talwalkar JA, Rosen CB et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010;34:27-34.
91. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-5.
92. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-72.
93. Cullen SN, Rust C, Fleming K et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
94. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
95. Al Mamari S, Djordjevic J, Halliday JS et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58:329-34.
96. Abarbanel DN, Seki SM, Davies Y et al. Immunomodulatory effect of vancomycin on treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33: 397-406.
97. Farkkila M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-86.
98. Boner AL, Peroni D, Bodini A et al. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharm 2007;20: 847-9.
99. Graziadei IW, Wiesner RH, Marotta PJ et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
100. Woodward J and Neuberger J. Autoimmune overlap syndromes. Hepatology 2001;33:994-1002.
101. Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
102. de Suray N, Van Beers B, Sempoux C et al. Autoimmune pancreatitis, sclerosing cholangitis, liver inflammatory pseudotumors, retroperitoneal fibrosis, lymphadenopathy, and sialoadenitis in a single patient: a multifaced expression of a hitherto unrecognized systemic autoimmune syndrome? Pancreas 2009;38:476-78.
103. Bjö rnsson E, Chari ST, Smyrk TC and Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007 Jun;45: 1547-54.
104. Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006;101:2070-5.
105. Zhang LL, Abraham SC, Leung S et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Modern Pathol 2009;22:1480.
106. Dastis SN, Latinne D, Sempoux C et al. Ulcerative colitis associated with IgG4 cholangitis: Similar features in two HLA identical siblings. J Hepatol 2009;51:601-5.